Winner
NURTuRE – Kidney Research UK
Partner(s): Evotec, UCB, AstraZeneca, AbbVie, Travere Therapeutics, Uni Birmingham, Uni Bristol, Uni Nottingham. Uk Renal registry, Hospitaux Univeritaires geneve, and Kidney Research UK
Executive Summary
The NURTuRE Biobank represents a groundbreaking multi-sector collaboration transforming kidney disease research through charity, NHS, academic and industry partnership. Led by Kidney Research UK, NURTuRE unites 14 NHS Trusts, top academic centres, global research institutes and major life-science companies to build the UK’s first national kidney biobank linking biological samples with longitudinal clinical, biomarker, imaging and genomics data.By bridging sectors that traditionally operate in isolation, this partnership generates a triple-win: 1) patients benefit from faster, more precise diagnosis and treatment; 2) the NHS gains a national infrastructure enabling real-world translational research; 3) industry partners access a scalable, ethically governed platform for innovation. With over 3,000 participants recruited and multiple therapeutic targets emerging, NURTuRE is delivering tangible impact that no single organisation could achieve alone.Choosing NURTuRE for “Multi-Sector Partnership of the Year” recognises its unique collaborative model, robust governance, and its capacity to align charitable mission, clinical care and scientific innovation to create lasting value across the healthcare ecosystem.
Highly commended
Co-producing UK clinical guidelines for Lysosomal Storage Disorders: A patient professional partnership – MPS Society
Partner(s): The PPPN, formally established by the LSD Collaborative in November 2023, brings together patient organisations, clinicians, specialist nurses, NHS England, diagnostic services, and the British Inherited Metabolic Disease Group (BIMDG). The guidelines are developed and maintained by the PPPN and remain its responsibility; they have not been signed off by NHS England
Executive Summary
The Patient Professional Partnership Network (PPPN) is a pioneering cross-sector initiative dedicated to improving care for people with lysosomal storage disorders (LSDs) across England. Established in November 2023 under the UK LSD Collaborative (a coalition of patient organisations), the PPPN brings together patient organisations, clinicians, specialist nurses, NHS England, diagnostic services, and the British Inherited Metabolic Disease Group (BIMDG) in a single collaborative forum.Its mission is to promote closer working relationships, strengthen clinical discussions, unite multiple stakeholders, and ensure meaningful patient engagement in decision-making. The PPPN’s leading achievement to date has been the development of co-produced national clinical guidelines for 11 LSD conditions that promote consistent, high-quality care regardless of treatment centre.This collaborative approach represents a transformative model for rare disease management. By combining clinical expertise with lived experience, the PPPN ensures that patients’ voices directly shape care standards and service delivery. The result is a system that is equitable, evidence-informed, and genuinely patient-centred. The PPPN demonstrates how true collaboration between professionals and patients can deliver sustainable, system-wide improvements, setting a new benchmark for integrated, patient-centred care in rare diseases.
Highly commended
The Power of Partnerships campaign to champion shared decision making in rare disease – ZPB Associates
Partner(s): ZPB Associates, BioCryst UK & Ireland and HAE UK
Executive Summary
“Sharing decisions with my consultant has changed my life dramatically.”Sian Harding, who lives with HAEThe Power of Partnerships campaign, led by ZPB and BioCryst UK Ltd in partnership with HAE UK – a small charity representing fewer than 1,500 hereditary angioedema (HAE) patients in the UK – and with input from Barts Health NHS Trust, sets new standards in rare disease care through genuine cross-sector collaboration. By championing shared decision making for HAE patients, the campaign was developed by working in partnership with the NHS, life sciences, and the patient community. The campaign’s innovative approach resulted in widely adopted patient tools, national media coverage, and measurable improvements in awareness and care. Notably, 87% of surveyed consultant immunologists had seen the campaign, 92% found the materials helpful, and 62% reported that it changed the way they or their colleagues interact with patients. This project stands out for its creative alliance, system-wide impact, and commitment to transforming patient outcomes for an underserved community.
Finalist
Ensuring Healthcare Access for Canal Boat Residents - Warwickshire North Boating Community Partnership
Executive Summary
This project addresses a critical health inequality affecting thousands of people living on canal boats across England and Wales. With no fixed address, limited transport, and unique lifestyle challenges, boaters often face barriers to accessing healthcare. The Warwickshire North Boating Community Partnership (WNBCP) a multi-sector partnership involving Healthwatch Warwickshire, two Primary Care Networks, the Canal & River Trust, emergency services, marinas, and local councils initiated a pioneering pilot in Warwickshire North. Preliminary findings revealed stark fears: ‘I am terrified of being taken ill as I fear getting care will be difficult.’ These insights shaped how we co-designed solutions such as training GP admin staff on temporary registrations, promoting the NHS App, and proposing floating health clinics. This initiative stands out for its creativity, inclusivity, and measurable impact. Outcomes include new training programs, improved signage, and wellbeing/ safety checks by emergency services. The model is scalable and replicable for other mobile populations. By bridging sector boundaries and amplifying unheard voices, this project demonstrates how collaboration can transform healthcare equity. It is a blueprint for tackling health inequalities in hard-to-reach communities, ensuring that mobility does not mean exclusion.
Finalist
The Good Patient Partnership Guide: Purpose driven patient-centricity
Executive Summary
The Good Patient Partnership Guide (GPPG) exemplifies the transformative power of multi-sector collaboration in healthcare. Since its launch in 2023, the GPPG has been co-created by a diverse coalition of patient groups, independent advocates, compliance and regulatory bodies, and independent standards organisations to co-create practical solutions that embed patient voices at every stage of the healthcare journey. This initiative moves beyond tokenistic engagement, fostering genuine co-creation and breaking down silos between sectors. Each annual edition delivers actionable insights, best practices, and innovative recommendations, driving system-wide improvements in patient care, health literacy, and service integration. The GPPG’s impact is evidenced by its adoption across diverse organisations, measurable improvements in patient engagement, and recognition as a catalyst for cultural change. Its unique approach – rooted in lived experience, creative thinking, and sustained partnership – sets it apart as a model for purposeful, patient-centric healthcare transformation. The GPPG inspires others to bridge sector boundaries and deliver meaningful, replicable outcomes for patients and the wider health ecosystem.
